I have extensive experience conducting clinical outcomes research related to blood and marrow transplantation (BMT). I have over 20 years of experience with inter- and intra-programmatic collaborative clinical and translational research to identify, understand and quantify the risk of adverse outcomes and long-term prognosis in hematologic malignancy patients treated with BMT. My research has investigated outcomes such as graft-versus-host disease, osteoporosis, chemotherapy-associated toxicity, infections and financial burden, as well as the impact of demographic and sociological factors such as age, obesity, place of residence, race, and socioeconomic status, on long-term prognosis after therapy with BMT. I have co-led multi-center, multi-disciplinary projects including:1) recipient and donor genetic susceptibility to transplant-related mortality after unrelated donor BMT, 2) immunophenotyping to detect minimal residual disease in myeloma patients treated on a 3-arm randomized controlled trial, 3) genetic susceptibility to AML, ALL and MDS. I have extensive experience leading and working as part of a variety of multidisciplinary teams on long-term projects involving complex data sources and structures. My teaching experience includes guest lectures on topics spanning ethical conduct of research, clinical epidemiology, blood & marrow transplant, and specific research projects, as well as one-on-one mentoring of students from all levels, including high school, college, graduate school, medical school, residency, clinical and graduate post-doc fellowships.
- Clay-Gilmour A, Hahn T, Preus L, Onel K, Skol A, Hungate E, Pasquini M, Spellman S, Zhu Q, Haiman CA, Stram DO, Pooler L, Sheng X, Yan L, Liu Q, Hu Q, Liu S, Battaglia S, Zhu X, Block A, Sait S, Weisdorf D, Ambrosone CB, Tritchler D, McCarthy PL, Sucheston-Campbell. Constitutional genetic risk of acute lymphoblastic leukemia in high-risk patients treated with allogeneic blood or marrow transplantation differs by sex and age. Blood Adv 1:1717-1728, 2017. Epub: http://www.bloodadvances.org/content/1/20/1717 PMID: 29296818, PMCID: PMC 5728332
- Ho CM, McCarthy PL, Wallace PK, Zhang Y, Fora A, Mellors P, Tario JD, McCarthy B, Chen GL, Holstein SA, Balderman SR, Cao X, Paiva B, Hahn T *. Immune signatures associated with improved progression free and overall survival for myeloma patients treated with AHCT. Blood Adv 1:1056-1066, 2017. Epub: http://www.bloodadvances.org/content/1/15/1056 PMID: 29296748 PMCID: 5728317
- Hahn T, Paplham P, Austin-Ketch T, Zhang Y, Grimmer J, Burns M, Balderman S, Ross M, McCarthy PL. Ascertainment of unmet needs and participation in health maintenance and screening of adult hematopoietic cell transplantation (HCT) survivors followed in a formal survivorship program. Biol Blood Marrow Transplant 23: 1968-73, 2017. PMID: 28782599
- Karaesmen E, Rizvi AA, Preus L, McCarthy PL, Pasquini MC, Onel K, Zhu X, Spellman S, Haiman CA, Stram DO, Pooler L, Sheng X, Zhu Q, Yan L, Liu Q, Hu Q, Webb A, Brock G, Clay-Gilmour AI, Battaglia S, Tritchler D, Liu S, Hahn T *, Sucheston-Campbell L. Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant. Blood 130: 1585-1596, 2017. PMID: 28811306 PMCID: PMC5620418
- Hahn T, Sucheston-Campbell LE, Preus L, Zhu X, Hansen JA, Martin PJ, Klein JP, Yan L, Liu S, Spellman S, Tritchler D, Clay A, Onel K, Pasquini M, McCarthy PL. Establishment of definitions and review process for consistent adjudication of cause-specific mortality after allogeneic unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 21:1679-86, 2015. PMID: 26028504